Lipid Efficacy/Tolerability Study (0524A-020)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,620

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions

Primary HypercholesterolaemiaMixed Hyperlipidaemia

Interventions

DRUG

niacin (+) laropiprant

Duration of Treatment - 24 weeks

DRUG

ER-niacin

Duration of Treatment - 24 weeks

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00269204 - Lipid Efficacy/Tolerability Study (0524A-020) | Biotech Hunter | Biotech Hunter